Treatment of Polyarteritis Nodosa
For newly diagnosed severe PAN, initiate combination therapy with cyclophosphamide and high-dose glucocorticoids (prednisone 1 mg/kg/day or IV methylprednisolone 500-1,000 mg/day for 3-5 days), while for nonsevere disease, use a non-glucocorticoid immunosuppressive agent (azathioprine, methotrexate, or mycophenolate mofetil) combined with glucocorticoids. 1
Disease Severity Stratification
First, determine disease severity as this fundamentally dictates treatment intensity:
Severe disease includes life- or organ-threatening manifestations:
- Renal disease
- Mononeuritis multiplex
- Muscle disease
- Mesenteric ischemia
- Coronary involvement
- Limb/digit ischemia
Nonsevere disease includes:
- Mild systemic symptoms
- Uncomplicated cutaneous disease
- Mild inflammatory arthritis 1
Treatment Algorithm for Severe PAN
Initial Induction Therapy
Cyclophosphamide + high-dose glucocorticoids is superior to glucocorticoids alone for severe disease 1. The 2021 ACR/Vasculitis Foundation guideline specifically recommends cyclophosphamide over rituximab for severe PAN, which differs from ANCA-associated vasculitis where these agents are considered equivalent 1.
Glucocorticoid dosing:
- IV pulse: methylprednisolone 500-1,000 mg/day (adults) for 3-5 days, preferred over oral high-dose
- High-dose oral: prednisone 1 mg/kg/day (up to 80 mg/day in adults) 1
Important caveat: Do NOT use plasmapheresis routinely with cyclophosphamide and glucocorticoids for non-HBV-associated PAN—the evidence does not support benefit 1. Plasmapheresis may only be considered in catastrophic cases unresponsive to aggressive immunosuppression.
Remission Maintenance
After achieving remission with cyclophosphamide (typically 3-6 months), transition to a less toxic agent such as azathioprine or methotrexate rather than continuing cyclophosphamide indefinitely 1. This recommendation is based on cyclophosphamide's significant toxicity profile and experience from ANCA-associated vasculitis.
Duration of immunosuppression: Discontinue non-glucocorticoid immunosuppressive therapy after 18 months of sustained remission rather than indefinite treatment 1. The majority of PAN patients experience monophasic disease, making indefinite therapy unnecessary in most cases.
Treatment Algorithm for Nonsevere PAN
Combine a non-glucocorticoid immunosuppressive agent with glucocorticoids rather than glucocorticoids alone 1. Options include:
- Azathioprine
- Methotrexate
- Mycophenolate mofetil
- Cyclophosphamide (if other agents fail)
This approach provides glucocorticoid-sparing effects and minimizes long-term glucocorticoid toxicity, which is particularly important in pediatric populations 1. While some patients achieve remission with glucocorticoids alone, approximately 40% ultimately require additional immunosuppression 2.
Glucocorticoid Tapering Strategy
The optimal duration of glucocorticoid therapy is not well-established—duration should be guided by clinical response rather than a fixed timeline 1. Evidence from other vasculitides suggests faster tapers increase flare risk, though flares are often mild and non-organ-threatening. Patient preference typically favors longer tapers prioritizing disease control over minimizing glucocorticoid toxicity.
Refractory Disease Management
For severe PAN refractory to glucocorticoids and non-cyclophosphamide immunosuppressants, switch to cyclophosphamide rather than simply increasing glucocorticoid doses 1. This recommendation is based on cyclophosphamide's demonstrated effectiveness in new-onset severe PAN.
Emerging evidence for refractory cases: A 2025 case report demonstrated successful use of upadacitinib (a JAK inhibitor) in a patient unresponsive to multiple immunosuppressants including tocilizumab, achieving remission and allowing complete immunosuppressant discontinuation 3. While this represents only a single case, it suggests JAK inhibitors may offer a breakthrough option when conventional therapies fail.
Special Considerations
DADA2 (Deficiency of Adenosine Deaminase 2)
If DADA2 is confirmed, strongly recommend TNF inhibitors over conventional immunosuppression 1. DADA2 presents as early-onset (often childhood) PAN-like vasculitis with recurrent strokes and skin changes. TNF inhibitors prevent strokes and are superior to cyclophosphamide in this genetic condition 4. Consider DADA2 testing in any PAN-like syndrome with strokes, particularly in younger patients.
HBV-Associated PAN
This guideline applies to systemic idiopathic PAN only. HBV-associated PAN requires antiviral therapy combined with plasma exchange rather than the immunosuppressive regimens described above 5, 6.
Adjunctive Therapy
Physical therapy is conditionally recommended for patients with nerve and/or muscle involvement 1. This carries minimal risk with potential benefit, particularly for those with substantial motor involvement.
Prognosis Context
With current treatment regimens, 5-year survival exceeds 80-92%, transforming PAN from a once uniformly fatal disease 7, 2. However, disease-free survival is significantly lower for microscopic polyangiitis compared to PAN, and approximately 40% of patients require additional immunosuppressive therapy beyond initial treatment 2.